TW202210504A - 對抗sars相關冠狀病毒之中和抗體 - Google Patents

對抗sars相關冠狀病毒之中和抗體 Download PDF

Info

Publication number
TW202210504A
TW202210504A TW110119505A TW110119505A TW202210504A TW 202210504 A TW202210504 A TW 202210504A TW 110119505 A TW110119505 A TW 110119505A TW 110119505 A TW110119505 A TW 110119505A TW 202210504 A TW202210504 A TW 202210504A
Authority
TW
Taiwan
Prior art keywords
amino acid
seq
acid sequence
variable region
chain amino
Prior art date
Application number
TW110119505A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬 貝克
亨寧 格魯爾
弗洛里安 克萊因
克里斯托夫 克里爾
馬蒂亞斯 策納
Original Assignee
德國科隆大學
德國馬爾堡菲利普大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德國科隆大學, 德國馬爾堡菲利普大學 filed Critical 德國科隆大學
Publication of TW202210504A publication Critical patent/TW202210504A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW110119505A 2020-05-29 2021-05-28 對抗sars相關冠狀病毒之中和抗體 TW202210504A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP20177354 2020-05-29
EP20177354.6 2020-05-29
EP20182325.9 2020-06-25
EP20182325 2020-06-25
EP20213562 2020-12-11
EP20213562.0 2020-12-11

Publications (1)

Publication Number Publication Date
TW202210504A true TW202210504A (zh) 2022-03-16

Family

ID=76250344

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110119505A TW202210504A (zh) 2020-05-29 2021-05-28 對抗sars相關冠狀病毒之中和抗體

Country Status (6)

Country Link
US (1) US20210371503A1 (enExample)
EP (1) EP4157455A1 (enExample)
JP (1) JP2023528826A (enExample)
CA (1) CA3180556A1 (enExample)
TW (1) TW202210504A (enExample)
WO (1) WO2021239935A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
BR112022024662A2 (pt) 2020-06-03 2023-04-04 Regeneron Pharma Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
US20240383968A1 (en) * 2020-12-11 2024-11-21 Boehringer Ingelheim International Gmbh Formulation for multi-purpose application
AU2022221297A1 (en) * 2021-02-09 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
WO2022263638A1 (en) * 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
US12496470B2 (en) * 2021-07-14 2025-12-16 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023150307A2 (en) * 2022-02-03 2023-08-10 Abpro Corporation Compositions and methods against a virus
CN118388640A (zh) * 2022-09-30 2024-07-26 郴州市第一人民医院 一种全人源抗新型冠状病毒SARS-CoV-2的广谱抗体及其应用
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Also Published As

Publication number Publication date
WO2021239935A9 (en) 2023-07-13
US20210371503A1 (en) 2021-12-02
EP4157455A1 (en) 2023-04-05
WO2021239935A1 (en) 2021-12-02
JP2023528826A (ja) 2023-07-06
CA3180556A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
TW202210504A (zh) 對抗sars相關冠狀病毒之中和抗體
TWI859420B (zh) 抗sars-cov-2抗體及使用其之方法
JP7498714B2 (ja) Ｂ型肝炎ウイルスを中和する抗体およびその使用
JP2023525039A (ja) Ｓａｒｓ－ｃｏｖ－２に対する抗体
JP2023523549A (ja) ＳＡＲＳ－ＣｏＶ－２に対する抗体およびそれを使用する方法
US20210079069A1 (en) Neutralizing anti-influenza binding molecules and uses thereof
JP2024507948A (ja) 呼吸器ウイルス感染症に対する防御抗体
US20250263467A1 (en) Antibody therapies for sars-cov-2 infection
US20210244825A1 (en) Il-21 antibodies
WO2021218879A1 (zh) Sars-cov-2中和抗体及其制备和应用
JP2024527607A (ja) 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体及び抗原結合断片
JP2023550785A (ja) 複数のベータコロナウイルスに結合する抗体
TW202144406A (zh) ＳＡＲＳ－ＣｏＶ－２抗體及其應用
CN116096402A (zh) 与抗人冠状病毒的中和抗体相关的方法和组合物
TW202440626A (zh) Sars-cov-2中和抗體
JP2012510802A (ja) 完全ヒトインフルエンザｍ２特異的抗体
JP2025526405A (ja) Ｒｓｖ及びｍｐｖパラミクソウイルスに対する広域中和抗体
TW202417477A (zh) 與多種嚴重急性呼吸道症候群β型冠狀病毒結合之抗體
TW202411247A (zh) 針對流感神經胺酸酶的廣泛中和抗體
WO2023230448A1 (en) Combination immunotherapy for influenza
JP2024533166A (ja) 小児被験体におけるＳＡＲＳ－ＣｏＶ－２感染の抗体療法
CN116724049A (zh) 针对sars相关冠状病毒的中和抗体
TW202204395A (zh) 抗sars-cov-2之抗體及使用其之方法
CN114761428A (zh) 抗血凝素抗体及其使用方法
CN118660905A (zh) 针对sars相关冠状病毒的中和抗体